• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Platelet transfusions are not recommended to treat cerebral hemorrhage for patients taking antiplatelet therapy

May 26, 2016

 

Transparent human Brain isolated on white background

Spontaneous intracerebral hemorrhages are often serious and may be fatal. Platelet transfusions are used to treat patients with hemorrhagic strokes associated with anti-platelet therapy. However, a new randomized, open-label, multi-center, phase 3 trial published in The Lancet surprisingly suggests that platelet transfusions may do more harm than good for these patients. Over 6 years, 97 patients were randomly assigned to receive platelet transfusions, and 93 received standard care. Patients receiving platelet transfusions had a higher odds of death at three months than those receiving standard care (adjusted odds ratio, 2.05 [95% CI, 1.18 – 3.56]; P=0.011); 23 patients (24%) in the platelet transfusion group died compared to 16 (17%) in the standard care group. Although this is a small, randomized trial, these data suggest that platelet transfusions should not be used to treat patients with intracerebral hemorrhagic stroke who were taking antiplatelet therapy.

 

References

 

  1. Baharoglu MI, Cordonnier C, Salman RA, de Gans K, Koopman MM, Brand A, Majoie CB, Beenen LF, Marquering HA, Vermeulen M, Nederkoorn PJ, de Haan RJ, Roos YB, Investigators P. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 2016.
  2. Prodan CI. Platelets after intracerebral haemorrhage: more is not better. Lancet 2016.

 

 

Filed Under

  • News
  • Platelet Transfusion

Recommended

  • COVID-19 Pandemic Impact on Transfusion Services: Elective Surgeries Resume, Convalescent Plasma Use Increases, and Blood Supply Drops to Critical Levels

  • Outpatient COVID-19 Convalescent Plasma Reduces Hospitalizations

  • Pre-Trauma Center Red Blood Cell Transfusions Are Beneficial

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Blood Donation Teams—a Novel Strategy to Support Novice Donors

  • Plasma Exchange to Reduce Biological Age

  • New Guidelines for Platelet Transfusion Recommend Restrictive Strategies

  • Directed Blood Donations Should be Limited

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley